Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) insider Noah Berkowitz sold 8,658 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.59, for a total transaction of $74,372.22. Following the sale, the insider now owns 110,023 shares of the company's stock, valued at approximately $945,097.57. The trade was a 7.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Arvinas Trading Up 3.3 %
ARVN opened at $8.70 on Thursday. The company has a market cap of $598.32 million, a price-to-earnings ratio of -3.14 and a beta of 1.95. The stock has a fifty day simple moving average of $16.65 and a two-hundred day simple moving average of $21.50. Arvinas, Inc. has a 12-month low of $7.91 and a 12-month high of $44.85.
Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period last year, the business posted ($2.53) earnings per share. On average, analysts predict that Arvinas, Inc. will post -3.81 EPS for the current year.
Analysts Set New Price Targets
A number of brokerages have commented on ARVN. Guggenheim decreased their price target on Arvinas from $57.00 to $32.00 and set a "buy" rating on the stock in a research note on Thursday, March 13th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arvinas in a research report on Friday, February 7th. BTIG Research started coverage on shares of Arvinas in a research report on Tuesday, December 10th. They issued a "buy" rating and a $69.00 price objective on the stock. Morgan Stanley lowered their price objective on shares of Arvinas from $48.00 to $12.00 and set an "equal weight" rating for the company in a research note on Thursday, March 13th. Finally, Bank of America cut their target price on Arvinas from $54.00 to $28.00 and set a "buy" rating on the stock in a research note on Wednesday, March 12th. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $37.47.
Check Out Our Latest Stock Report on Arvinas
Hedge Funds Weigh In On Arvinas
A number of institutional investors and hedge funds have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Arvinas in the 4th quarter worth approximately $42,332,000. Norges Bank bought a new stake in Arvinas in the fourth quarter worth $23,845,000. Boxer Capital Management LLC purchased a new stake in shares of Arvinas in the fourth quarter worth $20,294,000. Braidwell LP increased its holdings in shares of Arvinas by 148.3% during the third quarter. Braidwell LP now owns 1,284,472 shares of the company's stock valued at $31,637,000 after acquiring an additional 767,242 shares in the last quarter. Finally, RTW Investments LP raised its position in shares of Arvinas by 19.8% in the 4th quarter. RTW Investments LP now owns 3,334,308 shares of the company's stock worth $63,919,000 after purchasing an additional 551,979 shares during the last quarter. Institutional investors own 95.19% of the company's stock.
About Arvinas
(
Get Free Report)
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
